- Home
- CANF vs JZXN Comparison
CANF vs JZXN Comparison
Compare CANF & JZXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- JZXN
- Stock Information
- Founded
- CANF 1994
- JZXN 2019
- Country
- CANF Israel
- JZXN China
- Employees
- CANF N/A
- JZXN N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- JZXN Retail-Auto Dealers and Gas Stations
- Sector
- CANF Health Care
- JZXN Consumer Discretionary
- Exchange
- CANF Nasdaq
- JZXN Nasdaq
- Market Cap
- CANF 7.9M
- JZXN N/A
- IPO Year
- CANF N/A
- JZXN 2021
- Fundamental
- Price
- CANF $1.09
- JZXN $2.34
- Analyst Decision
- CANF Strong Buy
- JZXN
- Analyst Count
- CANF 2
- JZXN 0
- Target Price
- CANF $14.00
- JZXN N/A
- AVG Volume (30 Days)
- CANF 422.0K
- JZXN 359.2K
- Earning Date
- CANF 05-13-2025
- JZXN 05-19-2025
- Dividend Yield
- CANF N/A
- JZXN N/A
- EPS Growth
- CANF N/A
- JZXN N/A
- EPS
- CANF N/A
- JZXN N/A
- Revenue
- CANF $674,000.00
- JZXN $1,400,139.00
- Revenue This Year
- CANF $461.72
- JZXN N/A
- Revenue Next Year
- CANF N/A
- JZXN N/A
- P/E Ratio
- CANF N/A
- JZXN N/A
- Revenue Growth
- CANF N/A
- JZXN N/A
- 52 Week Low
- CANF $1.22
- JZXN $1.00
- 52 Week High
- CANF $4.69
- JZXN $7.82
- Technical
- Relative Strength Index (RSI)
- CANF 34.28
- JZXN 36.97
- Support Level
- CANF $1.13
- JZXN $1.54
- Resistance Level
- CANF $1.19
- JZXN $7.82
- Average True Range (ATR)
- CANF 0.11
- JZXN 1.20
- MACD
- CANF -0.02
- JZXN -0.42
- Stochastic Oscillator
- CANF 1.35
- JZXN 12.74
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).